JAMA Oncology APC and Open Access: AMA Pricing, ASCO Discounts, and Where It Fits Among Elite Cancer Journals

Here's the detail that changes the OA calculus at JAMA Oncology: all research articles become freely available on the JAMA Network website 12 months after publication. This happens automatically. You don't pay for it. You don't have to request it.

This means:

• Day 1-365: Your article is behind the JAMA Network paywall (unless you paid for gold OA). Subscribers, AMA members, and institutional library users can read it.
• Day 366+: Your article is free to read on the JAMA website. Anyone with an internet connection can access it.

The 12-month window matters because it reduces the urgency of paying for OA. If your funder doesn't require immediate open access, you can publish for free and your paper will be openly available within a year. For many NIH-funded researchers, this is the practical choice.

Compare this to journals like Nature, where subscription articles stay behind the paywall indefinitely unless the author pays for OA or the institution has a Read & Publish deal. JAMA Oncology's automatic free access after 12 months is genuinely generous.

ASCO members receive a 10% discount on JAMA Oncology's OA fee. This is notable because ASCO and the AMA are separate organizations. ASCO doesn't publish JAMA Oncology, but it has negotiated this benefit for its members.

The discount applies to the corresponding author's ASCO membership at the time of acceptance. If you're an active ASCO member, the discount is automatic once verified. You don't need to apply for it separately.

For early-career oncologists, ASCO membership ($150-$300/year depending on level) pays for itself quickly if you publish OA in JAMA Oncology even once. The 10% discount saves $500+ on a single article.

This cross-society discount is unusual. Most journals don't offer discounts based on membership in other organizations. The ASCO-AMA relationship reflects the overlapping readership between JCO (ASCO's flagship) and JAMA Oncology (AMA's oncology specialty journal).

Vanderbilt University has negotiated a pilot institutional agreement with the AMA that covers JAMA Network journal APCs for Vanderbilt-affiliated corresponding authors. This is one of the first institution-specific agreements for JAMA titles, and it signals where AMA institutional deals may be headed.

Under the Vanderbilt agreement:

• Vanderbilt researchers who publish in JAMA Oncology (or other JAMA Network journals) can have their OA APC covered by the institutional deal.
• The payment is handled between Vanderbilt's library and the AMA.
• The researcher doesn't pay out of pocket.

This is a pilot, not a widespread program. Most institutions don't have AMA-specific agreements. But if the Vanderbilt model proves successful, other major medical schools may negotiate similar deals. Watch for announcements from your institution's library about AMA partnerships.

For now, the practical reality for most researchers is that JAMA Oncology APCs come from grant funds or departmental budgets. The Vanderbilt pilot is the exception, not the rule.

The AMA's institutional agreement portfolio is growing but remains smaller than Springer Nature's or Elsevier's:

The key point: the AMA is an independent publisher. An Elsevier deal at your institution tells you nothing about JAMA Oncology. A Springer Nature deal tells you nothing either. You need an AMA-specific agreement, and most institutions don't have one yet.

Check with your library's scholarly communications team. Ask specifically about AMA journal coverage. If your institution is negotiating a new agreement, JAMA Oncology may be included in future deals.

Beyond the ASCO member discount, the AMA offers standard waiver programs:

Automatic geographical waivers:

• Authors from World Bank low-income countries receive full APC waivers for all JAMA Network journals.
• Authors from lower-middle-income countries receive partial reductions (typically 50%+).

Case-by-case hardship waivers:

• Available at acceptance. The AMA states that editorial decisions are independent of payment ability.
• Approval rates aren't published, but the AMA has a reputation for reasonable accessibility on waivers.

No AMA membership discount:

• AMA membership itself doesn't reduce the APC. Only ASCO membership provides a discount for JAMA Oncology.

Stacking discounts:

• Whether the ASCO member discount can be combined with geographical waivers depends on the specific circumstances. Ask the AMA production team at acceptance.

For NIH/NCI-funded oncology research, JAMA Oncology's 12-month free access window aligns perfectly with federal policy. Publish via the subscription track (free), deposit in PubMed Central, and your paper is publicly available within a year. No APC needed.

Plan S is the situation where you'll need to spend money. cOAlition S requires immediate OA with CC BY, which means paying ~$5,000-$5,500. The ASCO discount helps if you're a member. The Vanderbilt agreement helps if you're at Vanderbilt. Everyone else pays from grants.

Wellcome and HHMI typically cover APCs through their OA funding programs. If you have these funders, arrange payment before the invoice arrives.

JAMA Oncology publishes roughly 300-400 original research articles per year. Its editorial priorities include:

• Clinical trials across all cancer types, with emphasis on patient-reported outcomes
• Cancer epidemiology and population-level studies
• Health disparities in cancer care and outcomes
• Survivorship and long-term outcomes research
• Health services research and cancer care delivery
• Viewpoints and Commentaries (invited, free to read)

The journal's strength is at the intersection of clinical oncology and public health. If your study looks at cancer screening policy, disparities in treatment access, or survivorship after therapy, JAMA Oncology is a natural home. If your study is a straightforward Phase III trial, JCO or Lancet Oncology may be better fits.

JAMA Oncology's desk-rejection rate is roughly 75-80%. The journal is selective, but less so than JCO (85%+) or Lancet Oncology (80%+). Its acceptance rate is approximately 8-12%, depending on article type.

• The 12-month window changes the OA calculation. Don't pay $5,000+ for OA if your funder accepts delayed access. JAMA Oncology is one of the few elite journals that automatically frees articles after 12 months.
• License selection matters. CC BY vs CC BY-NC can affect both cost and funder compliance. Plan S requires CC BY. Choosing CC BY-NC when your funder needs CC BY creates a post-publication problem.
• ASCO discount requires active membership. Make sure your ASCO membership is current at the time of acceptance, not just at submission.
• AMA agreements are separate from everything else. Don't assume any non-AMA publisher deal covers JAMA Oncology.
• Word count limits are strict. JAMA Oncology enforces character/word limits more rigorously than some competitors. Manuscripts that exceed limits are returned before review.

JAMA Oncology's cost decision is simpler than it looks:

1. NIH/NCI-funded? Publish via subscription (free). Your paper is freely available after 12 months and in PMC. Done.
2. Plan S funder? Budget ~$5,000-$5,500 for CC BY OA. Use the ASCO discount if you're a member. Check if your institution has an AMA agreement.
3. Choosing between JAMA Oncology and JCO? JCO is free. Choose based on editorial fit, not cost.
4. Choosing between JAMA Oncology and Lancet Oncology? Lancet Oncology costs more and has a higher IF. Choose based on whether the IF premium matters for your career stage and whether your paper fits Lancet Oncology's preference for large international trials.
5. Budget-constrained but need OA? JAMA Network Open ($3,000) publishes oncology research and is fully gold OA.

The real differentiator for JAMA Oncology isn't cost. It's editorial identity. If your work sits at the intersection of cancer research and public health, disparities, or population science, JAMA Oncology offers a readership that JCO and Lancet Oncology don't fully match.

Before submitting, make sure your manuscript's framing emphasizes the population-level or public health angle that JAMA Oncology editors value. Run a free readiness scan to identify structural issues before they lead to desk rejection.

For the latest APC amounts and submission guidelines, visit the JAMA Oncology author instructions page.